Skip to main content
ANTX
NASDAQ Life Sciences

AN2 Therapeutics Reports 100% Parasite Elimination in Chagas Disease NHP Study, Advances to Phase 2

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$4.17
Mkt Cap
$150.187M
52W Low
$1
52W High
$6.91
52W Position info
317% above low
Off High info
40% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

ANTX has more than doubled off its 52-week low of $1 on light trading volume (0.1× avg).

Summary

AN2 Therapeutics announced highly positive results from two studies for its Chagas disease drug candidate, AN2-502998, showing 100% parasite elimination in nonhuman primates and a favorable safety profile in humans, paving the way for Phase 2.


Key Events · Product Development and Regulatory · ANTX

  • Positive NHP Study Results

    AN2-502998 achieved 100% parasite elimination in nonhuman primates with naturally acquired chronic Chagas disease, with durable results maintained for four months post-treatment and good tolerability.

  • Favorable Phase 1 Human Data

    The Phase 1 First-in-Human study showed AN2-502998 was generally well tolerated with no dose-limiting toxicities, and human plasma exposures met or exceeded NHP efficacy thresholds.

  • Advancement to Phase 2

    The company plans to initiate a Phase 2 proof-of-concept study for AN2-502998 later this year, targeting a potential multi-billion-dollar global market for Chagas disease.

  • Priority Review Voucher Eligibility

    AN2-502998, if approved, would be eligible for an FDA Tropical Disease Priority Review Voucher, which could add significant value to the program.


Analysis · ANTX · Life Sciences

This filing is highly important for AN2 Therapeutics as it provides strong clinical validation for its lead drug candidate, AN2-502998, in chronic Chagas disease. The 100% parasite elimination in a clinically relevant nonhuman primate model, combined with a clean safety profile and appropriate human exposure levels in Phase 1, significantly de-risks the program. Chagas disease represents a large unmet medical need with no FDA-approved treatments for adults, and the company projects a multi-billion-dollar market opportunity. Successful advancement to Phase 2, supported by these data, could be a major value inflection point for the company, especially given its recent capital raises.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 52.1% of the 217 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANTX was trading at $4.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $150.2M. The 52-week trading range was $1.00 to $6.91. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANTX - Latest Insights

ANTX
Nov 09, 2026, 7:33 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.00
Real-time Price: $4.46 info
Change: +$0.460 (+12%) info
Market Cap: $169.229M info
ANTX
Nov 02, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $4.54
Real-time Price: $4.46 info
Change: -$0.080 (-2%) info
Market Cap: $169.229M info
ANTX
Aug 11, 2026, 4:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.87
Real-time Price: $4.46 info
Change: -$1.41 (-24%) info
Market Cap: $169.229M info
ANTX
Aug 11, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.87
Real-time Price: $4.46 info
Change: -$1.41 (-24%) info
Market Cap: $169.229M info
ANTX
Aug 11, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.87
Real-time Price: $4.46 info
Change: -$1.41 (-24%) info
Market Cap: $169.229M info